Emerging targeted therapeutics underscore immunologic heterogeneity of asthma

Affiliations

¹ Washington University School of Medicine, St Louis, Mo.
² Washington University School of Medicine, St Louis, Mo. Electronic address: briankim@wustl.edu.

Editorial

Masato Tamari et al. J Allergy Clin Immunol. 2021 Sep.

. 2021 Sep;148(3):719-721.

doi: 10.1016/j.jaci.2021.07.008. Epub 2021 Jul 23.

¹ Washington University School of Medicine, St Louis, Mo.
² Washington University School of Medicine, St Louis, Mo. Electronic address: briankim@wustl.edu.

No abstract available

Keywords: Alarmin; IL-25; IL-33; JAK; TSLP; asthma.

Comment on

Inhaled JAK inhibitor GDC-0214 reduces exhaled nitric oxide in patients with mild asthma: A randomized, controlled, proof-of-activity trial.
Braithwaite IE, Cai F, Tom JA, Galanter JM, Owen RP, Zhu R, Williams M, McGregor AG, Eliahu A, Durk MR, Dengler HS, Zak M, Kenny JR, Wilson ME, Beasley R, Chen H. Braithwaite IE, et al. J Allergy Clin Immunol. 2021 Sep;148(3):783-789. doi: 10.1016/j.jaci.2021.02.042. Epub 2021 Mar 17. J Allergy Clin Immunol. 2021. PMID: 33744327 Clinical Trial.
Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial.
Kelsen SG, Agache IO, Soong W, Israel E, Chupp GL, Cheung DS, Theess W, Yang X, Staton TL, Choy DF, Fong A, Dash A, Dolton M, Pappu R, Brightling CE. Kelsen SG, et al. J Allergy Clin Immunol. 2021 Sep;148(3):790-798. doi: 10.1016/j.jaci.2021.03.044. Epub 2021 Apr 16. J Allergy Clin Immunol. 2021. PMID: 33872652 Clinical Trial.